Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Gains from Investment Securities (2020 - 2022)

PROCEPT BioRobotics (PRCT) has disclosed Gains from Investment Securities for 3 consecutive years, with $186000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Gains from Investment Securities rose 390.62% to $186000.0 in Q4 2022 year-over-year; TTM through Dec 2023 was $122000.0, a 24.49% increase, with the full-year FY2022 number at $22.9 million, up 35809.38% from a year prior.
  • Gains from Investment Securities was $186000.0 for Q4 2022 at PROCEPT BioRobotics, up from -$64000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $293000.0 in Q4 2020 to a low of -$64000.0 in Q4 2021.
  • A 3-year average of $97750.0 and a median of $81000.0 in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 121.84% in 2021, then skyrocketed 390.62% in 2022.
  • PROCEPT BioRobotics' Gains from Investment Securities stood at $293000.0 in 2020, then crashed by 121.84% to -$64000.0 in 2021, then surged by 390.62% to $186000.0 in 2022.
  • Per Business Quant, the three most recent readings for PRCT's Gains from Investment Securities are $186000.0 (Q4 2022), -$64000.0 (Q4 2021), and -$24000.0 (Q1 2021).